Form 4: Neurocrine Biosciences Director Leslie V. Norwalk Reports Stock Sale

Director Leslie V. Norwalk of Neurocrine Biosciences sold 1,106 shares of common stock at an average price of $141.8173, while also acquiring 2,100 shares through the vesting of restricted stock units.

Summary

• On May 17, 2024, Leslie V. Norwalk, a director of Neurocrine Biosciences Inc., reported transactions involving the company's common stock.
• Norwalk sold 1,106 shares at a weighted average price of $141.8173, with individual sales prices ranging from $140.81 to $142.71.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 28, 2023.
• Additionally, Norwalk acquired 2,100 shares through the vesting of restricted stock units (RSUs).
• Each RSU represents the right to receive one share of Neurocrine Biosciences' common stock.
• The RSU award was granted on May 17, 2023, and was fully vested on the transaction date.
• Following these transactions, Norwalk directly owns 994 shares of Neurocrine Biosciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The sale is pre-planned under a 10b5-1 plan, and the vesting of RSUs is a positive sign. However, any insider selling can create some uncertainty.

Positives

• The vesting of RSUs indicates a potential alignment of the director's interests with those of the shareholders.
• The director has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Negatives

• The sale of 1,106 shares by a director could be interpreted negatively by some investors, although it was executed under a pre-arranged trading plan.

Risks

• Sales by insiders, even under 10b5-1 plans, can sometimes create short-term negative sentiment around the stock.
• The market may react to insider selling regardless of the pre-planned nature of the transactions.

Future Outlook

The document does not contain specific forward-looking statements, but the ongoing execution of the 10b5-1 trading plan suggests continued sales may occur.

Industry Context

Insider transactions are common in publicly traded companies, and are closely monitored by investors as indicators of management's view of the company's prospects. Sales under 10b5-1 plans are generally viewed as less informative than discretionary sales, as they are pre-arranged.

Comparison to Industry Standards

• Comparing Norwalk's transactions to those of other directors in similar biotech companies would provide context.
• For example, if other directors are also selling shares under 10b5-1 plans, it might suggest a broader trend in the industry.
• Comparing the size of Norwalk's sale to her overall holdings and to the average trading volume of NBIX stock can also provide perspective.
• Companies like Amgen, Biogen, and Gilead Sciences could be used as benchmarks for comparison.

Stakeholder Impact

• Shareholders may react to the insider selling, although the pre-planned nature of the sale mitigates some concerns.
• The vesting of RSUs could be seen as a positive sign for employee morale.

Key Dates